📊 PROF Key Takeaways
Is Profound Medical Corp. (PROF) a Good Investment?
Profound Medical demonstrates strong revenue growth (50.7% YoY) and healthy gross margins (70.8%), indicating product-market demand. However, the company faces an unsustainable financial structure with massive operating losses (-$256.3% margin), negative operating cash flow (-$38.2M annually), and only ~1.5 years of cash runway at current burn rates, creating material liquidity risk without a clear near-term profitability path.
Why Buy Profound Medical Corp. Stock? PROF Key Strengths
- Strong YoY revenue growth of 50.7% reflects robust market demand for products
- Excellent gross margin of 70.8% demonstrates favorable product economics and pricing power
- Solid balance sheet with $59.7M cash reserves and minimal leverage (0.07x D/E)
PROF Stock Risks: Profound Medical Corp. Investment Risks
- Operating losses of $41.3M on $16.1M revenue create unsustainable -256% operating margin
- Negative operating cash flow of $38.2M annually depletes cash reserves within approximately 1.5 years without profitability or capital raise
- Operating expenses wildly exceed gross profit, indicating no clear path to breakeven absent major revenue acceleration or restructuring
Key Metrics to Watch
- Quarterly operating cash flow trend and timeline to cash flow breakeven
- Revenue growth rate sustainability and acceleration into profitability zone
- Operating expense growth rate relative to revenue growth rate
Profound Medical Corp. (PROF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.52x current ratio provides a solid financial cushion.
PROF Profit Margin, ROE & Profitability Analysis
PROF vs Healthcare Sector: How Profound Medical Corp. Compares
How Profound Medical Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Profound Medical Corp. Stock Overvalued? PROF Valuation Analysis 2026
Based on fundamental analysis, Profound Medical Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Profound Medical Corp. Balance Sheet: PROF Debt, Cash & Liquidity
PROF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Profound Medical Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.12 reflects profitable operations.
PROF Revenue Growth, EPS Growth & YoY Performance
PROF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$6.6M | $0.26 |
| Q2 2025 | $2.0M | -$6.6M | $0.28 |
| Q1 2025 | $1.2M | -$6.6M | $0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Profound Medical Corp. Dividends, Buybacks & Capital Allocation
PROF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Profound Medical Corp. (CIK: 0001628808)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PROF
What is the AI rating for PROF?
Profound Medical Corp. (PROF) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PROF's key strengths?
Claude: Strong YoY revenue growth of 50.7% reflects robust market demand for products. Excellent gross margin of 70.8% demonstrates favorable product economics and pricing power.
What are the risks of investing in PROF?
Claude: Operating losses of $41.3M on $16.1M revenue create unsustainable -256% operating margin. Negative operating cash flow of $38.2M annually depletes cash reserves within approximately 1.5 years without profitability or capital raise.
What is PROF's revenue and growth?
Profound Medical Corp. reported revenue of $16.1M.
Does PROF pay dividends?
Profound Medical Corp. does not currently pay dividends.
Where can I find PROF SEC filings?
Official SEC filings for Profound Medical Corp. (CIK: 0001628808) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PROF's EPS?
Profound Medical Corp. has a diluted EPS of $1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PROF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Profound Medical Corp. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PROF stock overvalued or undervalued?
Valuation metrics for PROF: ROE of -64.1% (sector avg: 15%), net margin of -264.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PROF stock in 2026?
Our dual AI analysis gives Profound Medical Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PROF's free cash flow?
Profound Medical Corp.'s operating cash flow is $-38.2M, with capital expenditures of $176.0K. FCF margin is -238.4%.
How does PROF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -264.4% (avg: 12%), ROE -64.1% (avg: 15%), current ratio 12.52 (avg: 2).